Search
Agalsidase alfa
go.drugbank.com/drugs/DB15874ApprovedInvestigational[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.
Alitretinoin
go.drugbank.com/drugs/DB00523ApprovedIt is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. It has also been approved for use in promyelocytic leukemia (leukemia, promyelocytic, acute). … An important regulator of gene expression during growth and development, and in neoplasms.
Famciclovir
go.drugbank.com/drugs/DB00426ApprovedInvestigationalFamciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles). … Famciclovir is a prodrug of penciclovir with higher oral bioavailability.
Favipiravir
go.drugbank.com/drugs/DB12466ApprovedInvestigationalDiscovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. … [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for
Prednicarbate
go.drugbank.com/drugs/DB01130ApprovedIt is used in the treatment of inflammatory skin diseases, such as atopic dermatitis. … IL-1a is also found in fibroblasts, where it is responsible for proliferation, collagenase induction and IL-6 synthesis, which are related to skin thickness.
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalIt is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043]. … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic
Tasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalTasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010. … Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness.
Synonyms: N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamideEtravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalIn 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development … Etravarine must always be used in combination with other antiretroviral drugs.
Clodronic acid
go.drugbank.com/drugs/DB00720ApprovedInvestigationalVet approved[A203111] Clodronic acid is not FDA approved, but is approved in Canada.[L13910] … [A1923] clodronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid]
Retifanlimab
go.drugbank.com/drugs/DB15766ApprovedInvestigational[L45603,L45613] The use of retifanlimab in combination with other oncology drugs for the treatment of metastatic gastroesophageal adenocarcinoma has also been evaluated.[A258383,A258388] … Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed